Breaking News

Advent in talks to buy Sanofi's Zentiva for €1.9B

Sanofi SA (SAN.FR) mentioned Tuesday that it had entered unique negotiations with Advent International Corp. to promote its European generic industry Zentiva for an undertaking price of one.92 billion euros ($2.37 billion).

The pharmaceutical company mentioned Advent had made a firm, binding and completely financed offer.

The transaction is anticipated to near by the end of 2018, following consultation with Sanofi workers' representatives, the corporate mentioned. It is subject to definitive agreements and regulatory approval, it added.

The divestment from Zentiva, a non-core industry, forms a part of Sanofi's technique to simplify the corporate.